EDU Price sensitive 27 Jan 2026, 8:36 AM

EDU expects to deliver towards the top end of FY25 guidance

EDU Holdings Ltd

EDU expects to deliver towards the top end of FY25 guidance

Key points

  • Revenue close to double, NPAT up more than 5 times the PCP
  • Ikon Institute responsible for significant majority of Group's operating earnings
  • Expansion into postgraduate market with 4 new courses in 2025

Full summary

EDU Holdings Limited (EDU) is pleased to advise that it expects to report FY25 results towards the top end of guidance. The company achieved strong performance in FY25, with revenue close to double and NPAT up more than 5 times the previous corresponding period (PCP). This was driven by the continued shift in mix to higher education, with Ikon Institute (Ikon), EDU's higher education business, responsible for the significant majority of the Group's operating earnings. In 2025, Ikon expanded into the postgraduate market, launching four new courses that together represented 17% of Trimester 3 enrolments. Looking ahead, the full-year impact of progressive enrolment growth in Ikon during 2025, its average course duration of approximately three years, and early indications of a strong Trimester 1, 2026 intake, position the Group well for 2026. Against the backdrop of challenging conditions in the VET sector, enrolments in Australian Learning Group (ALG), EDU's vocational education business, continue to soften, including in Term 1, 2026. Nevertheless, ALG continues to play a strategic role in supporting the Group's student diversity and providing pathway opportunities into Ikon. With a diversified student mix, expanded course offerings, multiple recruitment channels and balance sheet strength, the Company is well positioned to adapt to forthcoming regulatory changes in the international education sector.

Guidance

FY25 Revenue: $80.4m - $82.4m FY25 EBITDA: $24.1m - $25.6m FY25 NPAT: $13.6m - $15.1m

Outlook

The full-year impact of progressive enrolment growth in Ikon during 2025, its average course duration of approximately three years, and early indications of a strong Trimester 1, 2026 intake, position the Group well for 2026.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in